Robert Scannevin

Robert Scannevin

Company: Yumanity

Job title: Head of Research


Kenneth Rhodes, Ph.D., is chief scientific officer, Yumanity Therapeutics. Dr. Rhodes oversees the company’s integrated discovery platforms in addition to its drug discovery research programs. Dr. Rhodes was previously vice president, neurology discovery at Biogen, where he led an organization focused on discovery and early development of protein and small molecule drugs in the neurology therapeutic area.  Among the notable achievements of Dr. Rhodes’ group were the advancement of aducanumab (BIIB037; a monoclonal antibody for the treatment of Alzheimer’s disease, now in Phase III), opicinumab (BIIB033; a monoclonal antibody for myelin repair in multiple sclerosis, now in Phase II) and BIIB054 (a monoclonal antibody for the treatment of Parkinson’s disease, now in Phase II) into human clinical trials. Dr. Rhodes has more than 25 years of biopharmaceutical R&D experience spanning Wyeth, J&J, Biogen and Yumanity.  Dr. Rhodes is a longstanding member of the Children’s Hospital Boston Technology Development Fund, evaluating investments in translational drug discovery and development emerging from Children’s research programs.  His career has seen a consistent commitment and focus on finding new therapies for patients suffering from neurodegenerative diseases.   


Panel Discussion: Conducting a Strategic Analysis of Protein Misfolding Therapeutics 2:00 pm

• What are the strengths of companies active in developing protein misfolding therapeutics? • What is a bird’s eye view of the space in terms of how money has flowed in/out? • What do companies in this space need to change or improve to accelerate their scientific progress? • What is the market opportunity and…Read more

day: Day Two

Discovery & Clinical Translation of a Small-Molecule Inhibitor of α-Synuclein Toxicity 3:50 pm

• Using a yeast-to-human phenotypic screening platform we recently discovered that small molecule inhibitors of stearoyl-coA-desaturase (SCD) potently protect cells from α-synuclein toxicity • Preclinical data confirmed that reduction of fatty-acid desaturation is correlated with protection, providing a translational pharmacodynamic marker that can be used in animals and human studies • Focusing on the preclinical…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.